ProMIS Neurosciences (US:PMN) Globenewswire·2026-03-18 12:00Core Viewpoint - ProMIS Neurosciences, Inc. is advancing its research on therapies for Alzheimer's disease and other neurodegenerative disorders, presenting findings at the Alzheimer's & Parkinson's Diseases Conference 2026 [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases [4]. - The company utilizes its proprietary EpiSelect™ platform to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in diseases like Alzheimer's, ALS, and Parkinson's [4][8]. Research and Development - The company will present two scientific posters at the AD/PD™ 2026 conference, showcasing its proprietary discovery platform and its approach to targeting toxic misfolded proteins [1][2]. - The lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [5][6]. - PMN310 has received Fast Track designation from the U.S. FDA as of July 2025, indicating its potential in treating Alzheimer's disease [5]. Clinical Trials - ProMIS initiated the PRECISE-AD trial, a Phase 1b clinical study to evaluate the safety and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [6][7]. - The trial will assess the effects of PMN310 on biomarkers associated with Alzheimer's pathology and clinical outcomes, with a focus on safety and the risk of ARIA [7]. Presentation Details - The first presentation will focus on a vaccine designed against TDP-43 proteinopathies, while the second will discuss vaccination strategies targeting toxic alpha-synuclein species [3].